Search research articles
Contact Us
Filters
Showing results (151-160 of 205) with videos related to
Page
of 21
Sort By:
Leukemia
|
May 13, 2021
Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update
Timothy P Hughes, Nelma Cristina D Clementino, Mikhail Fominykh, et al.
British Journal of Haematology
|
July 13, 2017
Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd
Timothy P Hughes, Eduardo Munhoz, Marco Aurelio Salvino, et al.
Haematologica
|
December 31, 2011
Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib
Deborah L White, Jerald Radich, Simona Soverini, et al.
British Journal of Haematology
|
March 28, 2019
Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia
David M Ross, Ilaria S Pagani, Yazad D Irani, et al.
Blood
|
August 4, 2010
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
Timothy P Hughes, Andreas Hochhaus, Susan Branford, et al.
Blood
|
May 25, 2013
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M Ross, Susan Branford, John F Seymour, et al.
Cancer Letters
|
September 4, 2017
Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions
Teresa Sadras, Susan L Heatley, Chung H Kok, et al.
Blood
|
August 24, 2023
Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy
Ilaria S Pagani, Naranie Shanmuganathan, Phuong Dang, et al.
Blood
|
March 22, 2013
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
Susan Branford, David T Yeung, David M Ross, et al.
Science Advances
|
December 1, 2018
Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis
Denis Tvorogov, Daniel Thomas, Nicholas P D Liau, et al.
Page
of 21
Search research articles
Search
Showing results (151-160 of 205) with videos related to
Sort By:
Page
of 21
Leukemia
|
May 13, 2021
Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update
Timothy P Hughes, Nelma Cristina D Clementino, Mikhail Fominykh, et al.
British Journal of Haematology
|
July 13, 2017
Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd
Timothy P Hughes, Eduardo Munhoz, Marco Aurelio Salvino, et al.
Haematologica
|
December 31, 2011
Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib
Deborah L White, Jerald Radich, Simona Soverini, et al.
British Journal of Haematology
|
March 28, 2019
Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia
David M Ross, Ilaria S Pagani, Yazad D Irani, et al.
Blood
|
August 4, 2010
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
Timothy P Hughes, Andreas Hochhaus, Susan Branford, et al.
Blood
|
May 25, 2013
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
David M Ross, Susan Branford, John F Seymour, et al.
Cancer Letters
|
September 4, 2017
Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions
Teresa Sadras, Susan L Heatley, Chung H Kok, et al.
Blood
|
August 24, 2023
Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy
Ilaria S Pagani, Naranie Shanmuganathan, Phuong Dang, et al.
Blood
|
March 22, 2013
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
Susan Branford, David T Yeung, David M Ross, et al.
Science Advances
|
December 1, 2018
Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis
Denis Tvorogov, Daniel Thomas, Nicholas P D Liau, et al.
Page
of 21